Skip to main content

Advertisement

SpringerLink
Log in

Argatroban Attenuates Diabetic Cardiomyopathy in Rats by Reducing Fibrosis, Inflammation, Apoptosis, and Protease-Activated Receptor Expression

  • ORIGINAL ARTICLE
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Purpose

Chronic diabetes is associated with cardiovascular dysfunctions. Diabetic cardiomyopathy (DCM) is one of the serious cardiovascular complications associated with diabetes. Despite significant efforts in understanding the pathophysiology of DCM, management of DCM is not adequate due to its complex pathophysiology. Recently, involvement of protease-activated receptors (PARs) has been postulated in cardiovascular diseases. These receptors are activated by thrombin, trypsin, or other serine proteases. Expression of PAR has been shown to be increased in cardiac diseases such as myocardial infarction, viral myocarditis, and pulmonary arterial hypertension. However, the role of PAR in DCM has not been elucidated yet. Therefore, in the present study, we have investigated the role of PAR in the condition of DCM using a pharmacological approach. We used argatroban, a direct thrombin inhibitor for targeting PAR.

Methods

Type-2 diabetes mellitus (T2DM) was induced by high-fat feeding along with low dose streptozotocin (STZ 35 mg/kg, i.p. single dose) in male Sprague-Dawley rats. After 16 weeks of diabetes induction, animals were treated with argatroban at 0.3 and 1 mg/kg dose daily for 4 weeks. After 20 weeks, ventricular functions were measured using ventricular catheterization. Cardiac histology, TUNEL staining, and immunoblotting were performed to evaluate cardiac fibrosis, DNA fragmentation, and expression level of different proteins, respectively.

Results

T2DM was associated with cardiac structural and functional disturbances as evidenced from impaired cardiac functional parameters and increased fibrosis. There was a significant increase in PAR expression after 20 weeks of diabetes induction. Four weeks argatroban treatment ameliorated metabolic alterations (reduced plasma glucose and cholesterol), ventricular dysfunctions (improved systolic and diastolic functions), cardiac fibrosis (reduced percentage area of collagen in picro-sirius red staining), and apoptosis (reduced TUNEL positive nuclei). Reduced expression of PAR1 and PAR4 in the argatroban-treated group indicates a response towards inhibition of thrombin. In addition, AKT (Ser-473), GSK-3β (Ser-9), p-65 NFĸB phosphorylation, TGF-β, COX-2, and caspase-3 expression were reduced significantly along with an increase in SERCA expression in argatroban-treated diabetic rats which indicated the anti-fibrotic, anti-inflammatory, and anti-apoptotic potential of argatroban in DCM.

Conclusion

This study suggests the ameliorative effects of argatroban in diabetic cardiomyopathy by improving ventricular functions and reducing fibrosis, inflammation, apoptosis, and PAR expression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30(6):595–602.

    Article  CAS  PubMed  Google Scholar 

  2. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study JAMA. 1979;241(19):2035–8.

    CAS  PubMed  Google Scholar 

  3. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115(25):3213–23.

    Article  PubMed  Google Scholar 

  4. Ernande L, Derumeaux G. Diabetic cardiomyopathy: myth or reality? Arch Cardiovasc Dis. 2012;105(4):218–25.

    Article  PubMed  Google Scholar 

  5. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res. 2006;98(5):596–605.

    Article  CAS  PubMed  Google Scholar 

  6. Bloomgarden ZT. Glycemic control in diabetes: a tale of three studies. Diabetes Care. 2008;31(9):1913–9.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Cesario DA, Brar R, Shivkumar K. Alterations in ion channel physiology in diabetic cardiomyopathy. Endocrinol Metab Clin N Am. 2006;35(3):601–10. ix-x

    Article  CAS  Google Scholar 

  8. Aoki I, Shimoyama K, Aoki N, Homori M, Yanagisawa A, Nakahara K, et al. Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. J Am Coll Cardiol. 1996;27(3):560–6.

    Article  CAS  PubMed  Google Scholar 

  9. Ersoz G, Yakaryilmaz A, Turan B. Effect of sodium selenite treatment on platelet aggregation of streptozotocin-induced diabetic rats. Thromb Res. 2003;111(6):363–7.

    Article  CAS  PubMed  Google Scholar 

  10. Romano M, Guagnano MT, Pacini G, Vigneri S, Falco A, Marinopiccoli M, et al. Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab. 2003;88(11):5321–6.

    Article  CAS  PubMed  Google Scholar 

  11. Antoniak S, Owens AP 3rd, Baunacke M, Williams JC, Lee RD, Weithauser A, et al. PAR-1 contributes to the innate immune response during viral infection. J Clin Invest. 2013;123(3):1310–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Nickel KF, Laux V, Heumann R, von Degenfeld G. Thrombin has biphasic effects on the nitric oxide-cGMP pathway in endothelial cells and contributes to experimental pulmonary hypertension. PLoS One. 2013;8(6):e63504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Strande JL, Hsu A, Su J, Fu X, Gross GJ, Baker JE. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res Cardiol. 2007;102(4):350–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Sabri A, Muske G, Zhang H, Pak E, Darrow A, Andrade-Gordon P, et al. Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ Res. 2000;86(10):1054–61.

    Article  CAS  PubMed  Google Scholar 

  15. Strande JL, Hsu A, Su J, Fu X, Gross GJ, Baker JE. Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signaling. J Pharmacol Exp Ther. 2008;324(3):1045–54.

    Article  CAS  PubMed  Google Scholar 

  16. Bulani Y, Sharma SS. Therapeutic potential of targeting protease activated receptors in cardiovascular diseases. Curr Pharm Des. 2015;21(30):4392–9.

    Article  CAS  PubMed  Google Scholar 

  17. Sonin DL, Wakatsuki T, Routhu KV, Harmann LM, Petersen M, Meyer J, et al. Protease-activated receptor 1 inhibition by SCH79797 attenuates left ventricular remodeling and profibrotic activities of cardiac fibroblasts. J Cardiovasc Pharmacol Ther. 2013;18(5):460–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Sakai T, Nambu T, Katoh M, Uehara S, Fukuroda T, Nishikibe M. Up-regulation of protease-activated receptor-1 in diabetic glomerulosclerosis. Biochem Biophys Res Commun. 2009;384(2):173–9.

    Article  CAS  PubMed  Google Scholar 

  19. Waasdorp M, Duitman J, Florquin S, Spek CA. Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice. Sci Rep. 2016;6:33030.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005;52(4):313–20.

    Article  CAS  PubMed  Google Scholar 

  21. Mihara M, Aihara K, Ikeda Y, Yoshida S, Kinouchi M, Kurahashi K, et al. Inhibition of thrombin action ameliorates insulin resistance in type 2 diabetic db/db mice. Endocrinology. 2010;151(2):513–9.

    Article  CAS  PubMed  Google Scholar 

  22. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc. 2008;3(9):1422–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265–75.

    CAS  PubMed  Google Scholar 

  24. Ti Y, Xie GL, Wang ZH, Bi XL, Ding WY, Wang J, et al. TRB3 gene silencing alleviates diabetic cardiomyopathy in a type 2 diabetic rat model. Diabetes. 2011;60(11):2963–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Marsh SA, Dell'italia LJ, Chatham JC. Interaction of diet and diabetes on cardiovascular function in rats. Am J Physiol Heart Circ Physiol. 2009;296(2):H282–92.

    Article  CAS  PubMed  Google Scholar 

  26. Zhao SM, Wang YL, Guo CY, Chen JL, Wu YQ. Progressive decay of Ca2+ homeostasis in the development of diabetic cardiomyopathy. Cardiovasc Diabetol. 2014;13:75.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415(6868):198–205.

    Article  CAS  PubMed  Google Scholar 

  28. Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, Dillmann WH. Overexpression of the sarcoplasmic reticulum Ca (2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes. 2002;51(4):1166–71.

    Article  CAS  PubMed  Google Scholar 

  29. Vetter R, Rehfeld U, Reissfelder C, Weiss W, Wagner KD, Gunther J, et al. Transgenic overexpression of the sarcoplasmic reticulum Ca2+ATPase improves reticular Ca2+ handling in normal and diabetic rat hearts. FASEB J. 2002;16(12):1657–9.

    CAS  PubMed  Google Scholar 

  30. Suarez J, Scott B, Dillmann WH. Conditional increase in SERCA2a protein is able to reverse contractile dysfunction and abnormal calcium flux in established diabetic cardiomyopathy. Am J Physiol Regul Integr Comp Physiol. 2008;295(5):R1439–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Mishra PK, Metreveli N, Tyagi SC. MMP-9 gene ablation and TIMP-4 mitigate PAR-1-mediated cardiomyocyte dysfunction: a plausible role of dicer and miRNA. Cell Biochem Biophys. 2010;57(2–3):67–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Martin J, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F, et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-β. Cardiovasc Res. 2005;65(3):694–701.

    Article  CAS  PubMed  Google Scholar 

  33. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol. 2001;133(5):687–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331(19):1286–92.

    Article  CAS  PubMed  Google Scholar 

  35. Way KJ, Isshiki K, Suzuma K, Yokota T, Zvagelsky D, Schoen FJ, et al. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes. 2002;51(9):2709–18.

    Article  CAS  PubMed  Google Scholar 

  36. Kassel KM, Sullivan BP, Cui W, Copple BL, Luyendyk JP. Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease. Am J Pathol. 2012;181(4):1287–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Huisamen B. Protein kinase B in the diabetic heart. Mol Cell Biochem. 2003;249(1–2):31–8.

    Article  CAS  PubMed  Google Scholar 

  38. Bagul PK, Dinda AK, Banerjee SK. Effect of resveratrol on sirtuins expression and cardiac complications in diabetes. Biochem Biophys Res Commun. 2015;468(1–2):221–7.

    Article  CAS  Google Scholar 

  39. Tian R. Another role for the celebrity: Akt and insulin resistance. Circ Res. 2005;96(2):139–40.

    Article  CAS  PubMed  Google Scholar 

  40. Shamhart PE, Luther DJ, Hodson BR, Koshy JC, Ohanyan V, Meszaros JG. Impact of type 1 diabetes on cardiac fibroblast activation: enhanced cell cycle progression and reduced myofibroblast content in diabetic myocardium. Am J Physiol Endocrinol Metab. 2009;297(5):E1147–53.

    Article  CAS  PubMed  Google Scholar 

  41. Pawlinski R, Tencati M, Hampton CR, Shishido T, Bullard TA, Casey LM, et al. Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation. 2007;116(20):2298–306.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Sabri A, Short J, Guo J, Steinberg SF. Protease-activated receptor-1-mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation: distinct PAR-1 signaling pathways in cardiac fibroblasts and cardiomyocytes. Circ Res. 2002;91(6):532–9.

    Article  CAS  PubMed  Google Scholar 

  43. Spronk HM, De Jong AM, Verheule S, De Boer HC, Maass AH, Lau DH, et al. Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation. Eur Heart J. 2017;38(1):38–50.

    Article  PubMed  Google Scholar 

  44. Sugden PH, Fuller SJ, Weiss SC, Clerk A. Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br J Pharmacol. 2008;153(Suppl 1):S137–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes. 2002;51(6):1938–48.

    Article  CAS  PubMed  Google Scholar 

  46. Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol. 2006;48(8):1688–97.

    Article  CAS  PubMed  Google Scholar 

  47. Bhandari U, Kumar V, Kumar P, Tripathi CD, Khanna G. Protective effect of pioglitazone on cardiomyocyte apoptosis in low-dose streptozotocin & high-fat diet-induced type-2 diabetes in rats. Indian J Med Res. 2015;142(5):598–605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Guo Z, Xia Z, Jiang J, McNeill JH. Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine. Am J Physiol Heart Circ Physiol. 2007;292(4):H1728–36.

    Article  CAS  PubMed  Google Scholar 

  49. Suzuki H, Kayama Y, Sakamoto M, Iuchi H, Shimizu I, Yoshino T, et al. Arachidonate 12/15-lipoxygenase-induced inflammation and oxidative stress are involved in the development of diabetic cardiomyopathy. Diabetes. 2015;64(2):618–30.

    Article  CAS  PubMed  Google Scholar 

  50. Kellogg AP, Converso K, Wiggin T, Stevens M, Pop-Busui R. Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes. Am J Physiol Heart Circ Physiol. 2009;296(2):H453–61.

    Article  CAS  PubMed  Google Scholar 

  51. Kassel KM, Owens AP 3rd, Rockwell CE, Sullivan BP, Wang R, Tawfik O, et al. Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a western diet. Am J Pathol. 2011;179(5):2278–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the financial assistance from the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India (Project ID: NPLC-SSSharma) for this work.

Author information

Authors and Affiliations

  1. Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Sector-67, SAS, Nagar (Mohali), Punjab, 160062, India

    Yogesh Bulani & Shyam Sunder Sharma

Authors
  1. Yogesh Bulani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shyam Sunder Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shyam Sunder Sharma.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All the guidelines (national and institutional) for the care and use of animals were followed for conducting studies for this manuscript. Experimental protocol was approved (Protocol approval no. IAEC/14/63) by Institutional Animal Ethics Committee, NIPER, S.A.S. Nagar, Punjab, India.

Informed Consent

Not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bulani, Y., Sharma, S.S. Argatroban Attenuates Diabetic Cardiomyopathy in Rats by Reducing Fibrosis, Inflammation, Apoptosis, and Protease-Activated Receptor Expression. Cardiovasc Drugs Ther 31, 255–267 (2017). https://doi.org/10.1007/s10557-017-6732-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-017-6732-3

Keywords

Search

Navigation